Abstract
Objective To investigate the effects of β adrenergic receptor blocker carvedilol and cholinergic receptor blocker scopolamine on the biological behaviors of prostate cancer in C57BL/6 mice. Methods From June 2014 to November 2014, sixty male C57BL/6 mice, 10 weeks old, were injected with RM-1 cells (0.5×106) into bilateral dorsal prostate capsules of each mice by microsyringe and were randomly divided into three groups, including carvedilol group (K), scopolamine group (D) and saline group (N) after modeling. In K group, the carvedilol (10 mg/kg) was given to mice through gastric tube. The normal saline was given to them by subcutaneous injection. In D group, the normal saline was given to mice through gastric tube. Meanwhile, the scopolamine (1 mg/kg) was injected subcutaneously. In N group, daily normal saline was given by through gastric tube and subcutaneous injection. At the seventh day of postoperation, five mouse were sacrificed in each group every three days to observe the local growth, invasion and metastasis of prostate cancer to pelvic nodes and liver. Immunohistochemical determination of prostate tumor was made by TH staining and VAChT staining in each group. Results The volume of the prostate cancer was gradually increased in three groups. There was no statistical difference of prostate volume among three groups on the day 7 and 10 post-operatively (all P>0.05). The prostate volume of K group, D group and N group on the day 13 were 0.05±0.04, 0.18±0.08, 0.14±0.05 cm3, respectively (P 0.05). The AOD of TH and VAChT in prostate cancer of K group, D group and N group on the day 10 were [(0.0114±0.016), (0.114±0.002), (0.059±0.008)] and [(0.025±0.011), (0.0226±0.003), (0.009±0.003)], respectively (P 0.05). Conclusions β adrenergic receptor blocker carvedilol can suppress the growth of prostate cancer and cholinergic receptor blocker scopolamine may can inhibit metastasis of prostate cancer. Key words: Prostatic carcinoma; Mouse; Carvedilol; Scopolamine
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
